Skip to main content

Grifols SA

GRFS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001438569

No open-market purchases or sales by Grifols SA insiders were filed in the last 90 days; 164 institutions reported holding it in 13F filings for Q2 2026, worth $1.01B in total; no superinvestor holds it.

Other share classesGIFLFGIFOFGIKLY

Q1 2023 vs. Q4 2022

How the institutions holding Grifols SA changed between Q4 2022 and Q1 2023.

All holders in Q1 2023All holders in Q4 2022

13F holders of GRFS: Q4 2022 compared with Q1 2023
MeasureQ4 2022Q1 2023Change
Holders1271270
Shares104.5M114.5M+10.0M (+9.6%)
Value$888.4M$843.4M−$45.0M (−5.1%)

New holders (16)

Institutions that held Grifols SA at the end of Q1 2023 but not at the end of Q4 2022.

Institutions new to GRFS in Q1 2023
InstitutionSharesValue% of portfolio
Shay Capital LLC100,000$737.0K0.31%
Jump Financial, LLC70,936$522.8K0.02%
Campbell & CO Investment Adviser LLC32,315$238.2K0.04%
XTX Topco Ltd22,610$166.6K0.03%
Mercer Global Advisors Inc20,424$151.0K0.00%
Connor, Clark & Lunn Investment Management Ltd.15,441$113.8K0.00%
Vident Investment Advisory, LLC10,212$75.3K0.00%
Susquehanna International Securities, Ltd.10,080$74.3K0.05%
Zurcher Kantonalbank (Zurich Cantonalbank)2,966$21.9K0.00%
WR Wealth Planners, LLC811$5.98K0.00%
Bogart Wealth, LLC599$4.42K0.00%
Activest Wealth Management500$3.73K0.00%
UBS Asset Management Americas Inc375$2.77K0.00%
Allworth Financial LP78$5750.00%
Cape Investment Advisory, Inc.48$3540.00%
Proequities, Inc.9$660.00%

Sold out (16)

Institutions that held Grifols SA at the end of Q4 2022 and filed for Q1 2023 without it.